Omnicell, Inc. (NASDAQ:OMCL) EVP Dan S. Johnston sold 9,929 shares of Omnicell stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $85.47, for a total value of $848,631.63. Following the completion of the transaction, the executive vice president now owns 31,505 shares of the company’s stock, valued at approximately $2,692,732.35. The sale was disclosed in a document filed with the SEC, which is available at this link.
OMCL traded down $0.91 during trading on Friday, reaching $68.68. 361,957 shares of the stock traded hands, compared to its average volume of 597,114. The stock has a market cap of $2.83 billion, a PE ratio of 44.89, a price-to-earnings-growth ratio of 2.23 and a beta of 1.13. Omnicell, Inc. has a fifty-two week low of $52.20 and a fifty-two week high of $92.59. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.47 and a current ratio of 1.96. The firm’s 50-day moving average price is $82.00.
Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, April 25th. The company reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.38. Omnicell had a return on equity of 11.10% and a net margin of 4.74%. The company had revenue of $202.50 million during the quarter, compared to analysts’ expectations of $199.72 million. During the same quarter in the previous year, the firm earned $0.29 earnings per share. The business’s quarterly revenue was up 10.9% compared to the same quarter last year. On average, equities research analysts expect that Omnicell, Inc. will post 2.06 EPS for the current year.
Several brokerages have recently commented on OMCL. ValuEngine upgraded Valmont Industries from a “sell” rating to a “hold” rating in a research report on Friday, July 12th. TheStreet downgraded Trinity Industries from a “b” rating to a “c” rating in a research note on Thursday, April 25th. BidaskClub downgraded Amyris from a “hold” rating to a “sell” rating in a research note on Thursday, June 27th. Zacks Investment Research upgraded Triple-S Management from a “hold” rating to a “buy” rating and set a $26.00 target price on the stock in a report on Monday, April 29th. Finally, Benchmark reissued a “hold” rating on shares of Western Digital in a research report on Friday, April 26th. Five analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Omnicell has an average rating of “Buy” and an average price target of $79.89.
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Featured Story: Catch-Up Contributions
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.